▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1378 by analyst upside · 2026-08-14
DSGN
Design Therapeutics, Inc.
Healthcare · Market Cap $901M · P/E 0x
ANALYST PRICE TARGET
+45.9%
implied upside to consensus target
Current Price $14.39
Consensus Target $21.0
Bull Target $22.0
Bear Target $20.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $4.68
52-Week High $17.25
YTD Return +58.1%
FUNDAMENTALS
Market Cap $901M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.16
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.68
52-Week High $17.25
Current Price $14.39
Bear Target $20.0
Bull Target $22.0
● Now $14.39 ● Target $21.0
TRADING DATA
Avg Volume 924K
YTD Return +58.1%
Analyst Count 6
Consensus Buy
Upside to Target +45.9%
Last Updated 2026-08-14

ANALYST SUMMARY

Design Therapeutics, Inc. (DSGN) is currently trading at $14.39 with a Wall Street consensus price target of $21.0, implying potential upside of 45.9% over the next 12 months. 6 analysts currently cover DSGN, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $22.0, while the most cautious has a target of $20.0.

DSGN operates in the Healthcare sector with a market capitalisation of $901M. The stock is up 58.1% year-to-date and is currently trading near the upper end of its 52-week range of $4.68 – $17.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RIGL +36.3%
Rigel Pharmaceuticals, Inc.
$762M · P/E 2.5x · Buy
GMRS +38.8%
GMR Solutions Inc.
$754M · P/E 7.2x · Buy
ABUS +21.1%
Arbutus Biopharma Corporation
$906M · P/E 5.8x · Buy
IRWD +49.5%
Ironwood Pharmaceuticals, Inc.
$674M · P/E 5.2x · Buy
NUTX +42.6%
Nutex Health Inc.
$1B · P/E 6.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DSGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer - Reiterated
Outperform → Outperform 2026-05-04 14% win rate (7 calls)
Jefferies ● Initiated
Buy 2026-03-16 50% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-03-10 Building track record
Oppenheimer ● Initiated
Outperform 2026-01-07 14% win rate (7 calls)
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2025-12-03 29% win rate (7 calls)
RBC Capital ↑ Upgrade
Sector Perform → Outperform 2025-11-20 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-11-06 Building track record
RBC Capital reit
Sector Perform → Sector Perform 2024-08-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
15/30
Consensus clarity
27/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →